TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Anastrozole 1 mg Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers in the age between 19 to 55 years old~* Subjects were neither congenital nor chronic diseases.~* Subjects were selected after passing a clinical screening procedure that included a physical examination and laboratory tests.~* Availability of subject for the entire study period and willingness to adhere to protocol requirements, as evidenced by a signed Informed Consent Form.~Exclusion Criteria:~* Any history of a clinical condition which might affect drug absorption, distribution, metabolism or excretion or might be risk factors, e.g. clinically significant disorder in heart, liver, respiratory system, liver, kidney, gastrointestinal system and CNS~* Had a history of myocardial infarction, stroke, hypertension, arrhythmia, coronary artery disease, disease of neuropsychiatry, gastrointestinal system surgery (excluding appendectomy, herniotomy)~* Current clinically significant disorder in history taking or physical examination~* Acute disease within 14 days preceding the first application of study medication~* Had an relevant allergic disease~* Had history of hypersensitivity to drugs or any food~* Positive for Hepatitis B antigen, Hepatitis C antibody, HIV antibody, or High Quality Syphilis Reagin Test~* Excessive caffeine, alcohol intake and smoker(caffeine\>5 units/day, alcohol\>3 units/day(1 unit = pure alcohol 10ml), cigarettes\> 20 cigarettes /day)~* Subjects who excessive alcohol intake or drug which affect drug metabolism enzyme intake within 30 days preceding study~* History of drug abuse or positive for urinary testing of drugs abuse (amphetamine, barbiturates, cocaine, opioids, benzodiazepines etc.)~* Has donated whole blood within 60days or apheresis within 14days preceding the first application of study medication~* Received other investigational drug within 60days preceding the first application of study medication~* Taken any herbal medicine within 30days, prescription medication within 14 days or over-the-counter drug (except for vitamins, minerals) within 10days preceding the first application of study medication (might affect this study or safety of subjects as judged by the investigator)~* Subjects could not eat ASAN MEDICAL CENTER standard meal or were unsuitable for this study as judged by investigators

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Esomeprazole in Patients With Frequent Heartburn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant ,non-lactating females 18 years or older~* Experience heartburn at least 2 days a week~* Having heartburn that has responded to heartburn medication~* Must discontinue any current heartburn medications~Exclusion Criteria:~* Having a history of erosive esophagitis verified by endoscopy~* Having a history of GERD which was diagnosed by a physician~* Inability to take study medication or complete the study and all study procedures~* Subjects that have required more than one 14-day course of PPI treatment within the past 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Esomeprazole 20 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients with~* Epigastric pain of a hunger nature~* Pain at night in the epigastric region~* Increased appetite~Exclusion Criteria:~Patients with~* Functional or inflammatory diseases of the gastrointestinal tract liver and pancreas~* Metabolic, allergic and mental disease~* Hormone replacement therapy

- Gender: FEMALE
- Minimum Age: 49 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): Melatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
- Placebo (Type: PLACEBO_COMPARATOR): 1 tablet twice daily (period 6 months)
- Helicobacter pylori infected group (Type: OTHER): Pantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients need to be administered Zithromac Tablets 600mg in order to be enrolled in the surveillance.~Exclusion Criteria:~Patients not administered Zithromac Tablets 600mg.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: None): Patients taking Azithromycin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of American Society of Anesthesiologist(ASA) physical status 1 \& 2 requiring general anesthesia with endotracheal intubation.~* Duration of surgery more than 90 min~Exclusion Criteria:~* Those with preexisting hoarseness or sorethroat~* Smoker~* Vocal performer by occupation~* Recent or recurrent respiratory tract infection~* Risk factors for postoperative aspiration~* Obesity~* Pregnancy~* Receiving analgesics, corticosteroids and calcium channel blockers~* Contraindication to corticosteroid medications~* Anticipated difficult intubation~* Mallampati grade \> 2~* Difficult mask ventilation requiring oral or nasal airway~* Cormack and Lehman grade III and IV on laryngoscopy~* More than one intubation attempt~* Those requiring orogastric or nasogastric tubes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group LD: Lidocaine and Dexamethasone (Type: EXPERIMENTAL): lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
- Group L: Lidocaine (Type: ACTIVE_COMPARATOR): Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
- D: Dexamethasone (Type: ACTIVE_COMPARATOR): Dexamethasone 8 mg iv prior to induction of anesthesia
- N: normal saline (Type: PLACEBO_COMPARATOR): N: normal saline (placebo): 2 ml

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of 3 Different Bowel Cleansing Preparations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.~* At least 18 years of age~* If female, and of child-bearing potential, is using an acceptable form of birth control~* Negative urine pregnancy test at screening, if applicable~* In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study~Exclusion Criteria:~* Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.~* Subjects who had previous significant gastrointestinal surgeries.~* Subjects who have uncontrolled clinically significant pre-existing electrolyte disturbances.~* Subjects with severe liver or renal insufficiency.~* Subjects with a history of congestive heart failure or other clinically significant cardiac abnormality.~* Subjects with impaired consciousness that predisposes them to pulmonary aspiration.~* Subjects undergoing colonoscopy for foreign body removal and decompression.~* Subjects who are pregnant or lactating, or intending to become pregnant during the study.~* Subjects of childbearing potential who refuse a pregnancy test.~* Subjects allergic to any preparation components~* Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.~* Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BLI800 approved preparation regimen (Type: EXPERIMENTAL): BLI800 approved preparation regimen
- BLI800 investigational preparation regimen (Type: EXPERIMENTAL): BLI800 investigational preparation regimen
- PEG-3350 based bowel preparation (Type: ACTIVE_COMPARATOR): PEG-3350 based bowel preparation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pychoeducational Intervention for Women With Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. aged 18 to 75 years;~2. have type 2 diabetes greater than six months and being medically managed~3. score greater than or equal to 16 on the Center for Epidemiological Studies Depression (CES-D) scale which is indicative of depressive symptoms.~4. score greater than or equal to 12 on the CES-D plus a history of depression or currently being treated for depression.~Exclusion Criteria:~Women with current alcohol or substance abuse disorders, or a history of bipolar depression or any other psychotic disorder will be excluded.~Women will also be excluded if they have a diabetes knowledge test score of less than 70% and severe complications of diabetes (blindness, renal failure, or major amputation which includes most toes, foot, knee, or leg)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual medical care (Type: NO_INTERVENTION): Participants assigned to this arm represent the control group and will receive usual medical care only.
- Psychoeducational intervention (Type: EXPERIMENTAL): Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent before initiation of any study-related procedures~* Male or female patients aged 18 years or older~* Documented acute coronary syndrome and troponin negative and undergoing Ad Hoc percutaneous coronary intervention (PCI)~* Females must be post menopausal or surgically sterile~* Taking aspirin as an anti-platelet medication~Exclusion Criteria:~* Use of any thienopyridine or ticagrelor within 7 days prior to randomization~* Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve)~* Contraindication that ticagrelor or clopidogrel should not be administered Patient requires dialysis~* History of intolerance or allergy to aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor - 180 mg loading dose
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel - 600 mg loading dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Learn, Engage, Act, Process (LEAP) for MOVE!

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unit of randomization is facility.~* MOVE! group program in a VA Medical Center.~* MOVE! coordinators at medical centers who express interest in participating in the trial prior to the first cohort randomization.~Exclusion Criteria:~* Unit of randomization is facility.~* Facilities that are not a medical center e.g., community-based outpatient clinic, Veteran service center

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enhanced NCP Support (Type: ACTIVE_COMPARATOR): Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
- LEAP Intervention (Type: EXPERIMENTAL): Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-65 years~* DSM-IV Criteria BD I or II depressive episode,~* SIGH-ADS \>20; duration \>2 weeks.~* Stable dose antidepressant drug \>8 weeks with concurrent antimanic drug~* Controlled thyroid disease~* Subjects with preexisting eye diseases will be included.~* Able to provide informed consent~* Stable minimum dose antimanic drug \>4weeks: lithium 0.5 mEq/L, divalproex Na 50 mcg/mL, olanzapine 5mg daily, carbamazepine 4mg/L; lamotrigine 100mg daily, risperidone 2mg daily, quetiapine 400 mg daily, ziprasidone 10 mg bid, and aripiprazole 5 mg qd.~* Stable unchanged psychotherapy for \>16weeks~Exclusion Criteria:~* The following eye diseases: retinal disease, cataract surgery and lens removal, macular degeneration,~* Taking photosensitizing drugs such as phenothiazines (chlorpromazine), antimalarial drugs, melatonin and hypericum.~* Acute psychosis (DSM-IV Criteria)~* Rapid cycling in the past 1 year~* Obsessive compulsive disorder~* Alcohol or substance abuse or dependence in the past 6 months.~* MRS\>5~* Recent history of a suicide attempt (3 months) or active suicidal Ideation (SIGHADS item H11 \>2)~* Beta-adrenergic blockers, exogenous melatonin, chronic NSAIDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active Comparator (Type: ACTIVE_COMPARATOR): 7000lux broad-spectrum light
- Inactive Comparator (Type: PLACEBO_COMPARATOR): 50lux dim red light

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 20 to 60 years~* Presence of mono-infection of P. falciparum or P. vivax~* Weight between 40 kg to 90 kg~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria~* Mixed Plasmodium infection~* Presence of other serious or chronic clinical condition requiring hospitalization.~* Severe malnutrition~* Significant chronic medical conditions which in the opinion of the investigator preclude enrollment into the study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
- Cohort 2 (Type: EXPERIMENTAL): 10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD~* 10 pack-year or greater history of cigarette smoking~* Post-bronchodilator FEV1/FVC of \<0.7~* Predicted FEV1 of 70% of normal or less~* Modified Medical Research Council (mMRC) dyspnea score of 2 or greater~Exclusion Criteria:~* Women who are pregnant, lactating, or planning to become pregnant~* Respiratory disorders other than COPD, including a current diagnosis of asthma~* Clinically significant non-respiratory diseases or abnormalities that are not adequately controlled~* Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the excipients of magnesium stereate or lactose used in the inhaler delivery device~* Hospitalization for COPD or pneumonia within 12 weeks prior to screening~* Lung volume reduction surgery within 12 weeks prior to screening~* Abnormal and clinically significant ECG findings at screening~* Clinically significant laboratory findings at screening~* Use of systemic corticosteroids, antibiotics for respiratory tract infections, high dose inhaled steroids (\>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit~* Use of long-term oxygen therapy (12 hours or greater per day)~* Regular use of nebulized treatment with short-acting bronchodilators~* Participation in the acute phase of a pulmonary rehabilitation program~* A know or suspected history of alcohol or drug abuse~* Affiliation with the investigational site~* Previous use of GSK573719 or the combination of GSK573719/GW642444

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK573719 (Type: EXPERIMENTAL): active drug
- Placebo (Type: PLACEBO_COMPARATOR): no active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age ≥ 18 years~2. willing to have bilateral femoral perineural catheters placed with a subsequent ropivacaine infusion and motor/sensory testing for 6 hours, requiring an overnight stay in the UCSD GCRC/CTRI to allow dissipation of local anesthetic infusion effects by the following morning~Exclusion Criteria:~1. current daily analgesic use~2. opioid use within the previous 4 weeks~3. any neuro-muscular deficit of either femoral nerves and/or quadriceps muscles~4. morbid obesity \[weight \> 35 kg/m2\]~5. pregnancy (as determined by a urine pregnancy test prior to any study interventions)~6. incarceration~We expect to recruit a maximum of 30 healthy volunteers; with a target goal of 24 for the analysis. Selection for inclusion will not be based on gender, race, or socioeconomic status. The study population of interest includes men and women of all races and socioeconomic status. There will be no participants from vulnerable populations, such as pregnant women, children, or prisoners.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4% (Type: EXPERIMENTAL): Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
- RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1% (Type: ACTIVE_COMPARATOR): Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete